Table: Kyowa Kirin -9-MTH group results (IFRS)
Nov 1 (Reuters)-
Kyowa Kirin Co., Ltd.
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
9 months ended 9 months ended Year to
Sep 30, 2023 Sep 30, 2022 Dec 31, 2023
LATEST YEAR-AGO COMPANY
RESULTS RESULT FORECAST
Sales 306.05 283.78 426.00
(+7.9 pct) (+11.7 pct) (+6.9 pct)
(+1.5 pct)
Operating
Pretax 64.34 60.40 86.00
(+6.5 pct) (+44.2 pct) (+27.3 pct)
Net 53.55 49.21 70.00
(+8.8 pct) (+49.5 pct) (+30.7 pct)
EPS Basic 99.62 yen 91.57 yen 130.23 yen
EPS Diluted 99.61 yen 91.55 yen
Ann Div 51.00 yen 54.00 yen
-Q2 Div 27.00 yen 24.00 yen
-Q4 Div 27.00 yen 27.00 yen
NOTE - Kyowa Kirin Co., Ltd..
(Figures are reported based on international accounting rules (IFRS).)
If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half
dividend and Q4 to the second-half dividend announced before a new corporate law in
2006 allowed companies to pay and report dividends on a quarterly basis.
*Net - represents Net profit attributable to owners of the parent company.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4151.T
Recent news on Kyowa Kirin
See all newsFactbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Factbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Brief: Kyowa Kirin Announces Agreement With US Administration To Reduce Treatment Costs For Americans
Table: Kyowa Kirin 6-MTH group results (IFRS)
Brief: Kyowa Kirin Says European Commission Approves Crysvita For Infants With X-Linked Hypophosphataemia